Nsair Ahmad, Hupin David, Chomette Stéphanie, Barthélémy Jean Claude, Roche Frédéric
Service de Physiologie Clinique et de l'Exercice, CHU de Saint-Etienne, Saint-Étienne, France.
EA SNA EPIS 4607, Université de Lyon, Université Jean Monnet, Saint-Étienne, France.
Front Neurol. 2019 Aug 2;10:801. doi: 10.3389/fneur.2019.00801. eCollection 2019.
Obstructive sleep apnea/hypopnea (OSAH) affects more than 15% of the general population and increases the occurrence of cardiovascular (CV) and metabolic events. Continuous positive airway pressure (CPAP) treatment is currently the gold standard treatment of OSAH and could prevent the occurrence of such events. However, long-term adherence to CPAP is a problem where a significant rate stop device treatment use. OSAH patients suffering CV disease could be less compliant due to less diurnal symptoms. We performed a prospective study of 408 non-CV or CV disease patients suffering severe OSAH syndrome and followed them during the first 5 months as well as a mean of 3 years of CPAP treatment use. We demonstrated that in adult OSAH patients that two variables were associated with a low compliance (<5 h/night): age <60 y and lower maximal positive airway pressure level used. There was no significant impact of the presence of CV disease on compliance of 5 months. After 3 years of CPAP, age <60 y as well as diabetes were independent factors of low compliance. There was no significant association between gender, mask types, 90th centile positive airway pressure level, apnea/hypopnea index and short- or long-term compliance in our population. We did not find lower compliance of CPAP in CV OSAH patients. Most of our population (68-73%) demonstrated an optimal night treatment duration at 3 years of follow-up, allowing a reduction of CV occurrence or recurrence. We hypothesize that an early and short education of OSAH as we routinely proposed could allow a significant increase in the optimal observance of CPAP in at-risk populations.
阻塞性睡眠呼吸暂停低通气综合征(OSAH)影响超过15%的普通人群,并增加心血管(CV)和代谢事件的发生风险。持续气道正压通气(CPAP)治疗是目前OSAH的金标准治疗方法,可预防此类事件的发生。然而,长期坚持使用CPAP是一个问题,相当比例的患者停止使用该设备进行治疗。患有CV疾病的OSAH患者可能因日间症状较少而依从性较差。我们对408例患有严重OSAH综合征的非CV或CV疾病患者进行了一项前瞻性研究,并在最初5个月以及平均3年的CPAP治疗期间对他们进行了随访。我们证明,在成年OSAH患者中,两个变量与低依从性(<5小时/晚)相关:年龄<60岁和使用的最大气道正压水平较低。CV疾病的存在对5个月时的依从性没有显著影响。CPAP治疗3年后,年龄<60岁以及糖尿病是低依从性的独立因素。在我们的研究人群中,性别、面罩类型、第90百分位数气道正压水平、呼吸暂停/低通气指数与短期或长期依从性之间没有显著关联。我们没有发现CV OSAH患者的CPAP依从性较低。我们的大多数研究人群(68-73%)在3年随访时显示出最佳的夜间治疗时长,这使得CV事件的发生或复发有所减少。我们假设,按照我们常规建议对OSAH进行早期和简短的教育,可以显著提高高危人群对CPAP的最佳依从性。